DMAC
DiaMedica Therapeutics Inc.8.76
+0.09+1.04%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
456.20MP/E (TTM)
-Basic EPS (TTM)
-0.71Dividend Yield
0%Recent Filings
8-K
8-K
8-K
Q3 loss widens; trials advance
DiaMedica Therapeutics reported Q3 2025 net loss of $8.6M, up from $6.3M last year, driven by higher R&D on ReMEDy2 stroke trial—now nearing 50% of 200-patient interim target—and preeclampsia IST, where Part 1a expansion enrolls after dose escalation completion. Cash hit $55M, funding ops into 2H 2027. Progress accelerates, yet FDA pre-IND feedback awaits.
10-Q
Q3 FY2025 results
DiaMedica posted a Q3 operating loss of $9.0M, up 31% y/y from $6.9M (derived), driven by R&D ramp to $6.4M from $5.0M as ReMEDy2 AIS trial expands globally and Phase 2 PE study advances to Part 1b on positive interim safety data. Nine-month net loss hit $24.0M versus $16.5M y/y, with EPS at -$0.53 on 45.2M diluted shares—anti-dilutive options excluded. Cash plus marketable securities swelled to $55.3M on $30.0M net from July private placement, funding ops 12+ months despite $21.3M nine-month opex burn. No debt. Equity issuances diluted shares 22% y/y. Interim PE data looks solid. Litigation with ICON/PRA settled October 31. Clinical delays persist.
10-Q
Q2 FY2025 results
DiaMedica's Q2 losses widened to $8.0M operating and $7.7M net, up 42% y/y from $5.6M and $5.1M, driven by R&D ramp to $5.8M from $3.9M as ReMEDy2 expands globally and PE Phase 2 advances with promising interim safety data showing blood pressure drops. Cash burn hit $14.7M YTD, yet $30.0M in cash plus marketable securities holds steady; July's $29.9M private placement bolsters runway. No debt weighs the balance sheet. Trials face enrollment delays.
CALC
CalciMedica, Inc.
5.22+0.59
DNTH
Dianthus Therapeutics, Inc.
41.40-0.52
DRMA
Dermata Therapeutics, Inc.
2.32-0.16
DSGN
Design Therapeutics, Inc.
9.62+0.50
DYN
Dyne Therapeutics, Inc.
19.55-0.04
MNOV
MediciNova, Inc.
1.48-0.04
MTVA
MetaVia Inc.
8.14-0.17
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
STOK
Stoke Therapeutics, Inc.
33.61+0.63